Selective amylin receptor agonist · Investigational

Eloralintide 10mg

Eloralintide (LY3841136) · 10mg vial

Eloralintide is an investigational, long-acting peptide designed to selectively activate amylin receptors. Amylin is a pancreatic hormone co-secreted with insulin that is involved in satiety, gastric emptying and glucose regulation.

Pricing · per vial

Mix & match any vials — 2–4 −10%, 5+ −15%
Retail1 vialR1,400
2–4−10%R1,260
5+−15%R1,190

In transit · ETA 20 Nov

How it works

Rather than acting on GLP-1 or GIP receptors, eloralintide targets the amylin pathway, which signals fullness and slows gastric emptying. Its extended half-life supports a once-weekly research schedule.

Research context

A 48-week phase 2 trial published in The Lancet evaluated once-weekly doses from 1mg to 9mg in adults with obesity or overweight. It remains investigational and is not approved by any regulator.

Vial contents & handling

  • 10mg eloralintide
  • Single lyophilised vial

Quality & sourcing. Sourced from established manufacturers who test using HPLC analysis. COA available on request — ask us on WhatsApp ↗

Storage: keep unopened lyophilised vials in a cool, dark place. Once reconstituted, store in the fridge at 2–8°C and use within 2 months.

Research reference dosage

10mg vial · 3ml water · 3.33mg/ml
LevelAmountU100 unitsFrequency
Beginner1mg30 units1× weekly · any time
Intermediate2.5mg75 units1× weekly · any time
Advanced5mg150 units1× weekly · any time

Fixed 3ml · U100 device (1 unit = 0.01ml). Long-acting, once-weekly profile; titrate gradually. Advanced (150 units) exceeds one 100-unit syringe fill. Research reference only.

Dosing status: No approved dose. Trial dose levels describe study design and are not instructions for these vials.

References

Guides

Research use only · Not for human or veterinary consumption · Not for self-administration